Corbenic Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Corbenic Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-58	Closed	-$14K	–	259
2020 Q4	$14K	Hold	58	–	–	0.01%	114
2020 Q3	$16K	Sell	58 -11	-16%	-$3.04K	0.01%	96
2020 Q2	$20K	Hold	69	–	–	0.01%	86
2020 Q1	$16K	Hold	69	–	–	0.01%	89
2019 Q4	$15K	Buy	+69	New	+$14K	0.01%	111
2017 Q4	–	Sell	-78	Closed	-$12K	–	248
2017 Q3	$12K	Buy	+78	New	+$11.7K	0.02%	138
2017 Q1	–	Sell	-24	Closed	-$2K	–	218
2016 Q4	$2K	Hold	24	–	–	﹤0.01%	185
2016 Q3	$2K	Buy	+24	New	+$2.27K	﹤0.01%	183
2015 Q1	–	Sell	-38	Closed	-$5K	–	216
2014 Q4	$5K	Buy	+38	New	+$4.28K	﹤0.01%	163

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Corbenic Partners's VRTX Position: Q1 2021 in Review

Corbenic Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 58 shares — an estimated $14K sold.

Corbenic Partners first reported a position in VRTX in Q4 2014 and held it in 9 quarters. The position peaked at $20K in Q2 2020. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Corbenic Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Corbenic Partners sold 58 Vertex Pharmaceuticals shares in Q1 2021, an estimated $14K.
Corbenic Partners first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Corbenic Partners's Vertex Pharmaceuticals position peaked at $20K in Q2 2020.
999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Corbenic Partners's 13F filing for Q1 2021, filed 14 Apr 2021.